A 61-year-old woman with advanced Hodgkin lymphoma began chemotherapy with the ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) regimen. Which of the following molecular actions most likely mediated the therapeutic effect of doxorubicin in the patient’s disease?

A 47-year-old man with non-Hodgkin lymphoma was admitted to the hospital to receive his fourth cycle of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen plus rituximab. Physical examination revealed tachycardia, shortness of breath that worsened soon after lying flat, neck vein distention, pulmonary rales, and ankle edema. Which of the following drugs most likely caused these adverse effects?

A 6-year-old boy suffering from acute lymphoblastic leukemia started combination maintenance therapy. One of the administered drugs is inactive in its parent form and must be metabolized by the enzyme hypoxanthine-guanine phosphoribosyl transferase into a monophosphate nucleotide. Which of the following drugs undergoes this activation?

A patient with multiple myeloma was started on therapy that included a drug that acts via inhibition of the 26S proteasome. Which of the following drugs is most likely this proteasomal inhibitor?

A cancer cell that is resistant to the effects of both vincristine and methotrexate has probably developed the resistance as a result of which of the following mechanisms?

A 23-year-old man with Hodgkin’s lymphoma was treated unsuccessfully with the MOPP regimen (mechlorethamine, vincristine, prednisone, procarbazine). He subsequently underwent a successful course of therapy with the ABVD regimen (doxorubicin, bleomycin, vinblastine, dacarbazine). Which of the following classes of anticancer drugs used in the treatment of this patient is cell cycle specific (CCS) and used in both the MOPP and ABVD regimens?

A 28-year-old man with Hodgkin’s lymphoma was treated with the ABVD regimen. The patient developed dyspnea, a nonproductive cough, and intermittent fever. Chest x-ray film revealed pulmonary infiltration. If these problems are due to the anticancer drugs to which he has been exposed, which of the following is the most likely causative agent?

If allopurinol is used adjunctively in cancer chemotherapy to offset hyperuricemia, the dosage of this anticancer drug should be reduced.

This agent is used in combination therapy for non-Hodgkin’s lymphoma. Due to its selectivity, it is expected to be less myelosuppressive compared with the classic agents.

This antimetabolite inhibits DNA polymerase and is one of the most active drugs in AML. Although myelosuppression is dose limiting, the drug may also cause cerebellar dysfunction, including ataxia and dysarthria.

A patient with non-Hodgkin’s lymphoma is treated with a combination of that includes bleomycin, cyclophosphamide, vincristine, doxorubicin, and prednisone. Dexrazoxane is thought to protect against the distinctive toxicity of which drug in this patient’s regimen?

This immunotherapeutic agent binds to CD19-expressing tumor cells in patients with refractory B-cell precursor ALL.

All of the following agents are Bcr-Abl tyrosine kinase inhibitors used in the treatment of Chronic Myelogenous leukemia (CML), however only this agent is effective in CML that harbors the T315I gatekeeper mutation.

Which of the following agents is an anti-PD-1 immune checkpoint inhibitor used in the treatment of Hodgkin’s lymphoma that is refractory to standard chemotherapy treatment?

Which of the following agents is a granulocyte colony-stimulating factor that is used to limit the duration of neutropenia in patients receiving myelosuppressive chemotherapy regimens.

Which of the following agents is a recombinant urate-oxidase enzyme indicated for the management of plasma uric acid levels in pediatric and adult patients with leukemia and lymphoma that are receiving chemotherapy expected to result in tumor lysis and elevation of plasma uric acid?

This monoclonal antibody targets CD52 and is used in the treatment of Chronic lymphocytic leukemia.

This monoclonal antibody is directed against CD38 on multiple myeloma cells?

Our patient received a 40mg/m² dose of doxorubicin. What is final calculated dose in mg of doxorubicin that he will receive?